A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety and tolerability of elexacaftor (ELX, VX-445)
in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA).